Q2
Founded Yoda Pharmaceuticals Inc. in the Cayman Islands.
Company Overview
Pioneering CNS Research
Dasher Neuroscience is dedicated to pioneering research in central nervous system (CNS) diseases. By integrating artificial intelligence (AI) technology, Dasher Neuroscience aims to drive groundbreaking advances, offering innovative treatment options for patients worldwide.
Our History and Achievements
Dasher Neuroscience Yoda Pharmaceuticals Inc. brings together top-tier researchers and physicians from leading universities and research institutions in Taiwan. Incubated through Taiwan’s national initiative and Stanford University’s global SPARK program, Dasher Neuroscience is at the forefront of integrating state-of-the-art AI technology into pharmaceutical research, specializing in developing innovative drugs for Central Nervous System (CNS) disorders.
Flagship Therapy: YA-101
YA-101, our flagship drug for Multiple System Atrophy (MSA), has received Orphan Drug Designation in the US, EU, and Japan, as well as Fast Track Designation from the US FDA, and is in Phase II trials in the US, Japan, and Taiwan.
Pipeline & Global Vision
Beyond YA-101, Dasher Neuroscience’s development pipeline focuses on neurodegenerative and neurodevelopmental disorders, targeting diseases such as Parkinson’s disease, Alzheimer’s disease, and schizophrenia. Driven by our mission to address unmet medical needs, we are committed to delivering innovative, effective, safe, and convenient treatment options for patients worldwide.
The Impact of AI in Drug Development
AI is transforming drug development in the pharmaceutical industry by rapidly identifying drug candidates, predicting efficacy and toxicity, and optimizing molecular design. It accelerates discovery, streamlines clinical trials, and improves prediction accuracy to reduce failures. By shortening development timelines and lowering costs, AI is enabling safer, more efficient, and accessible therapies.
Global Collaborations and Partnerships
At Dasher Neuroscience, we collaborate globally to drive the development of innovative therapies for CNS disorders. By integrating expertise across the scientific, clinical, technological, and regulatory landscape, we accelerate the translation of research into safe, effective, and transformative treatments. Our efforts create meaningful opportunities to address unmet medical needs in the CNS field, bringing hope to patients and their families worldwide. We are committed to continuous collaboration, knowledge sharing, and pioneering innovation, striving to advance therapies that truly improve lives and shape the future of neurological and neurodevelopmental care.
